temsirolimus
information and resources from the National Cancer Institute
temsirolimus
An ester analog of rapamycin. CCI-779 binds to and inhibits the mammalian target of rapamycin (mTOR), resulting in decreased expression of mRNAs necessary for cell cycle progression and arresting cells in the G1 phase of the cell cycle. mTOR is a serine/threonine kinase which plays a role in the PI3K/AKT pathway that is upregulated in some tumors.temsirolimus
An ester analog of rapamycin. CCI-779 binds to and inhibits the mammalian target of rapamycin (mTOR), resulting in decreased expression of mRNAs necessary for cell cycle progression and arresting cells in the G1 phase of the cell cycle. mTOR is a serine/threonine kinase which plays a role in the PI3K/AKT pathway that is upregulated in some tumors.
|
|
|
|
news articles
Wyeth Terminates Phase 3 Clinical Program With Oral Temsirolimus ... Mar 16, 2006
Trading Markets, WYE | charts | news | Powerrating) revealed the termination of HORIZON phase 3 clinical trial program of its investigational drug temsirolimus oral tablets in ...
Termination Of Phase 3 Clinical Program With Oral Temsirolimus In ... Mar 20, 2006
Medical News Today (press release), NYSE: WYE), announced today its decision to discontinue the HORIZON phase 3 clinical trial program of Wyeth's investigational drug temsirolimus oral tablets in ...
Wyeth Pharma Discontinues Phase 3 Trial Of Temsirolimus Oral ... Mar 16, 2006
Trading Markets, WYE | charts | news | Powerrating), announced that it would discontinue the HORIZON phase 3 clinical trial of its investigational drug temsirolimus oral tablets ...
Wyeth Pharmaceuticals Announces Termination of Phase 3 Clinical ... Mar 16, 2006
PR Newswire (press release), Ongoing Phase 3 Studies With IV Temsirolimus in Renal Cell Carcinoma and Mantle Cell Lymphoma Continue MADISON, NJ, March 16 /PRNewswire-FirstCall/ -- Wyeth ...
Wyeth: breast cancer prospects receive a blow Mar 23, 2006
Pharmaceutical Business Review By Staff Writer. Wyeth has terminated a phase III trial of temsirolimus in metastatic post-menopausal breast cancer. Wyeth has discontinued ...
Wyeth halts phase III trial of anticancer agent Mar 20, 2006
Pharmaceutical Business Review Wyeth Pharmaceuticals has discontinued a phase III clinical trial program of its investigational drug temsirolimus oral tablets for the treatment of hormone ...
Wyeth Stops Breast Cancer Trial Mar 16, 2006
TheStreet.com ...its own. The phase III trial involved the experimental drug temsirolimus plus the already-approved breast cancer drug Femara. The ...
Wyeth wins more diet drug trials Mar 23, 2006
Pharmaceutical Business Review ...just days beforehand the termination of a phase III clinical program evaluating an oral formulation of its cancer treatment candidate temsirolimus in women ...
NEWS RELEASE Mar 20, 2006
Financial News USA (press release), NYSE: WYE), announced recently its decision to discontinue the HORIZON phase 3 clinical trial program of Wyeth's investigational drug temsirolimus oral tablets ...
Wyeth Ends Phase III Cancer Drug Trial Mar 16, 2006
MSN Money Wyeth was testing its investigational treatment, temsirolimus oral tablets, combined with Femara, a Novartis drug that's already approved for breast cancer ...
(PRN) - PFF Bancorp Inc. to Host Fourth Quarter Earnings ... Mar 16, 2006
Bolsamania.com, ...[+]. (PRN) - Wyeth Pharmaceuticals Announces Termination of Phase 3 Clinical Program with Oral Temsirolimus in Women with Metastatic Breast Cancer ... [+. ...
Temsirolimus May Improve Effectiveness of Femara® in Advanced ... Dec 14, 2005
Cancer Consultants (press release), Researchers from Europe recently reported results from a phase II clinical trial indicating that the addition temsirolimus to Femara® (letrozole) resulted in ...
Temsirolimus (CCI-779) May Improve Effectiveness of Femara in ... Dec 15, 2005
Cancer Consultants (press release), Researchers from Europe recently reported results from a randomized, 3-arm, phase II study indicating that the addition temsirolimus to Femara® (letrozole ...
Temsirolimus Equivalent to Currently Used Chemotherapy in ... Nov 21, 2005
DG News PHILADELPHIA, PA -- November 21, 2005 -- A high level of activity was seen at an early stage of clinical research with temsirolimus in women with metastatic and ...
Wyeth working on new breast cancer drug Dec 8, 2005
CNN Temsirolimus, the experimental breast cancer drug, nearly doubles the survival time in breast cancer patients when it is combined with the Novartis drug Femara ...
Breast Cancer Patients Benefit from Treatment with Investigational ... Dec 12, 2005
DG News Symposium (SABCS), Dr. Baselga explained that he and colleagues recruited 92 patients in a phase 2 study of add-on therapy with temsirolimus -- a specific ...
|
|
